Hepatoma Research: the beginning of a new forum

References

[1] Surveillance Research Program, National Cancer Institute Fast Stats: an interactive tool for access to SEER cancer statistics; November 10, 2011. Available from: http://www.seer.cancer.gov/ faststats.[Last accessed on 2015 Feb 04].

[2] Ferlay J,Bray F,Mathers C.Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008..Int J Cancer2010;127:2893-917

[3] Pourhoseingholi MA,Baghestani AR.Burden of gastrointestinal cancer in Asia: an overview..Gastroenterol Hepatol Bed Bench2015;8:19-27 PMCID:PMC4285928

[4] Liver Cancer. Available from: http://www.livestrong.com. [Last accessed on 2015 Feb 04]

[5] Amin J,O'Connell DL,Tracey E,Law MG.Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study..J Hepatol2006;45:197-203

[6] Ulcickas Yood M,Guo D,Shan J,Skovron ML,Caldwell C.Incidence of hepatocellular carcinoma among individuals with hepatitis B virus infection identified using an automated data algorithm..J Viral Hepat2008;15:28-36

[7] World Health Organization..International Agency for Research on Cancer..IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Hepatitis Viruses. Vol. 59.1994;Lyon, FranceInternational Agency for Research on Cancer

[8] Nguyen VT,Dore GJ.Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden..J Viral Hepat2009;16:453-63

[9] But DY,Yuen MF.Natural history of hepatitis-related hepatocellular carcinoma..World J Gastroenterol2008;14:1652-6 PMCID:PMC2695904

[10] Bruno S,Colombo M,Benvegnù L,Ascione A,Piccinino F,Mangia A,Persico M,Almasio PL.Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study..Hepatology2007;45:579-87

[11] Lok AS,Wright EC,Kim HY,Everson GT,Lee WM,Dienstag JL,Morishima C.Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C..Gastroenterology2011;140:840-9 PMCID:PMC3057272

[12] Kwon H.Does antiviral therapy prevent hepatocellular carcinoma?.Antivir Ther2011;16:787-95

[13] Bugianesi E,Vanni E,Brunello F,Musso A,Capussotti L,Rizzetto M.Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma..Gastroenterology2002;123:134-40

[14] Stickel F.Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications..Gut2010;59:1303-7

[15] Tsukuma H,Tanaka S,Yabuuchi T,Nakanishi K,Inoue A,Kawashima T.Risk factors for hepatocellular carcinoma among patients with chronic liver disease..N Engl J Med1993;328:1797-801

[16] El-Serag HB,Petersen NJ.The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update..Ann Intern Med2003;139:817-23

[17] Liu CJ,Chen PJ,Huang WL,Chen DS.Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study..J Infect Dis2006;194:594-9

[18] Yang HI,Chen PJ,Jen CL,Wang LY,You SL,Liaw YF.Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma..J Natl Cancer Inst2008;100:1134-43 PMCID:PMC2518166

[19] Iannacone M,Ruggeri ZM.HBV pathogenesis in animal models: recent advances on the role of platelets..J Hepatol2007;46:719-26 PMCID:PMC1892635

[20] Reid AE,Aiza I,Reddy R,Lau JY,Liang TJ.Hepatitis C virus genotypes and viremia and hepatocellular carcinoma in the United States..Am J Gastroenterol1999;94:1619-26

[21] Liang TJ.Pathogenesis of hepatitis C-associated hepatocellular carcinoma..Gastroenterology2004;127:S62-71

[22] Hassan MM,Hatten CJ,Li D,Beasley P.Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus..Hepatology2002;36:1206-13

[23] Davis GL,El-Serag H,Jennings LW.Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression..Gastroenterology2010;138:513-21, 521.e1-6

[24] Lok AS,Morgan TR,Sterling RK,Everson GT,Lee WM,Dienstag JL,Morishima C.Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease..Gastroenterology2009;136:138-48 PMCID:PMC3749922

[25] Yang HI,Su J,Liaw YF,Chen CJ.Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection..J Clin Oncol2010;28:2437-44

[26] Kiyosawa K,Ichijo T,Yoshizawa K,Tanaka E.Hepatocellular carcinoma: recent trends in Japan..Gastroenterology2004;127:S17-26

[27] El-Serag HB.Hepatocellular carcinoma: recent trends in the United States..Gastroenterology2004;127:S27-34

[28] Ascha MS,Lopez R,Feldstein AF.The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis..Hepatology2010;51:1972-8

[29] Li P,Li Y,Liu X.Expression of Wnt-5a and ß-catenin in primary hepatocellular carcinoma..Int J Clin Exp Pathol2014;7:3190-5 PMCID:PMC4097247

[30] Bruix J.Management of hepatocellular carcinoma..Hepatology2005;42:1208-36

[31] Donato F,Puoti M.A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma..Int J Cancer1998;75:347-54

[32] Donato F,Gelatti U,Boffetta P,Decarli A,Ribero ML,Porru S.Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women..Am J Epidemiol2002;155:323-31

[33] Zhang BH,Tang ZY.Randomized controlled trial of screening for hepatocellular carcinoma..J Cancer Res Clin Oncol2004;130:417-22

[34] Trevisani F,Rapaccini G,Benvegnù L,Grazi GL,Di N.Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience)..Am J Gastroenterol2002;97:734-44

[35] Bolondi L,Siringo S,Casali A,Piscaglia F,Zanetti M.Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis..Gut2001;48:251-9 PMCID:PMC1728189

[36] Outwater EK.Imaging of the liver for hepatocellular cancer..Cancer Control2010;17:72-82

[37] Colli A,Casazza G,Colucci A,Duca P.Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review..Am J Gastroenterol2006;101:513-23

[38] Davila JA,Richardson PA,McGlynn KA.Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States..Hepatology2010;52:132-41 PMCID:PMC3835698

[39] Marrero JA,Nghiem HV,Fontana RJ.Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass..Liver Transpl2005;11:281-9

[40] Mitchell DG,Sherman M.LI-RADS (Liver Imaging Reporting and Data System): Summary, discussion, and consensus of the LI-RADS Management Working Group and future directions..Hepatology2015;61:1056-65

[41] von Herbay A,Gregor M.Contrast-enhanced ultrasound with SonoVue: differentiation between benign and malignant focal liver lesions in 317 patients..J Clin Ultrasound2010;38:1-9

[42] Kim JI,Choi JY,Kim SH,Han JK.The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver..Invest Radiol2008;43:202-10

[43] Llovet JM,Bruix J.Prognosis of hepatocellular carcinoma: the BCLC staging classification..Semin Liver Dis1999;19:329-38

[44] Grieco A,Caminiti G,Covino M,Rapaccini GL.Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre..Gut2005;54:411-8 PMCID:PMC1774422

[45] Marrero JA,Barrat A,Conjeevaram HS,Lok AS.Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort..Hepatology2005;41:707-16

[46] Llovet JM,Bruix J.Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation..Hepatology1999;30:1434-40

[47] Forner A.East meets the West – portal pressure predicts outcome of surgical resection for hepatocellular carcinoma..Nat Clin Pract Gastroenterol Hepatol2009;6:14-5

[48] Breitenstein S,Petrowsky H."State of the art" in liver resection and living donor liver transplantation: a worldwide survey of 100 liver centers..World J Surg2009;33:797-803

[49] Tung-Ping Poon R,Wong J.Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma..Ann Surg2000;232:10-24 PMCID:PMC1421103

[50] Poon RT.Prevention of recurrence after resection of hepatocellular carcinoma: a daunting challenge..Hepatology2011;54:757-9

[51] Mazzaferro V,Doci R,Pulvirenti A,Montalto F,Morabito A.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis..N Engl J Med1996;334:693-9

[52] Freeman RB,Edwards E,Merion R,United Network for Organ Sharing.Results of the first year of the new liver allocation plan..Liver Transpl2004;10:7-15

[53] Graziadei IW,Waldenberger P,Nachbaur K,Margreiter R.Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome..Liver Transpl2003;9:557-63

[54] Vilana R,Bru C,Solé M.Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma..Hepatology1992;16:353-7

[55] Lencioni R.A critical appraisal of the literature on local ablative therapies for hepatocellular carcinoma..Clin Liver Dis2005;9:301-14, viii

[56] May JP.Hyperthermia-induced drug targeting..Expert Opin Drug Deliv2013;10:511-27

[57] Kulik LM,van Holsbeeck L,Lewandowski RJ,Hunter RD,Abecassis MM,Salem R.Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation..J Surg Oncol2006;94:572-86

[58] Sangro B,Cianni R,Gasparini D,Paprottka PM,Van Buskirk M,Ettorre GM,Giampalma E,Wilhelm K,Izzo F,Maini CL,Cappelli A,Ahmadzadehfar H,Lastoria S.Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation..Hepatology2011;54:868-78

[59] Llovet JM,Monta-a X,Coll S,Ayuso C,Muchart J,Rodés J.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial..Lancet2002;359:1734-9

[60] Llovet JM.Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival..Hepatology2003;37:429-42

[61] Georgiades CS,D'Angelo M.Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis..J Vasc Interv Radiol2005;16:1653-9

[62] Varela M,Burrel M,Sala M,Ayuso C,Monta-á X,Bruix J.Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics..J Hepatol2007;46:474-81

[63] Poon RT,Pang RW,Woo R,Fan ST.A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead..Clin Gastroenterol Hepatol2007;5:1100-8

[64] Li X,Zheng CS,Liu X.Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level..World J Gastroenterol2004;10:2878-82 PMCID:PMC4572123

[65] Llovet JM,Mazzaferro V,Gane E,de Oliveira AC,Raoul JL,Schwartz M,Zeuzem S,Greten TF,Seitz JF,Häussinger D,Shan M,Voliotis D.Sorafenib in advanced hepatocellular carcinoma..N Engl J Med2008;359:378-90

[66] Cheng AL,Chen Z,Qin S,Luo R,Ye S,Xu J,Liang H,Wang J,Pan H,Zou J,Guan Z.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial..Lancet Oncol2009;10:25-34

[67] Park JW,Kim JS,Li RK,Thomas M,Baudelet C,Raoul JL.Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma..Clin Cancer Res2011;17:1973-83